19 Nov 2019 15:38
C4X Discovery Holdings plc
("C4XD" or the "Company")
Director Dealings
C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, announces that further to the Company's announcement on 24 October 2019, the following subscriptions for shares by Directors were made in its recent Capital Raising on the same terms as other investors:
Clive Dix, Chief Executive Officer, subscribed for 133,334 ordinary shares of 1 penny each in C4XD ("Ordinary Shares") at a price of 15 pence per Ordinary Share. Following the transaction, Clive Dix has a total interest of 1,588,920 Ordinary Shares, representing 1.47% of the total voting rights in the Company.
Craig Fox, Chief Scientific Officer, subscribed for 7,355 Ordinary Shares at a price of 15 pence per Ordinary Share pursuant to the Open Offer. Following the transaction Craig Fox has a total interest of 14,538 Ordinary Shares, representing 0.01% of the total voting rights.
Natalie Walter, Non-executive Director, subscribed for 66,666 Ordinary Shares at a price of 15 pence per Ordinary Share. Following the transaction Natalie Walter has a total interest of 66,666 Ordinary Shares, representing 0.06% of the total voting rights.
Harry Finch, Non-executive Director, subscribed for 66,673 Ordinary Shares at a price of 15 pence per Ordinary Share pursuant to the Open Offer. Following the transaction Harry Finch has a total interest of 388,098 Ordinary Shares, representing 0.36% of the total voting rights.
Capitalised terms used but not otherwise defined in this announcement bear the meaning ascribed to them in the circular issued by the Company on 25 October 2019.
For further information, please contact:
C4X Discovery Holdings plc
Clive Dix, Chief Executive Officer 07801 865 803
Panmure Gordon (UK) Limited (NOMAD) 020 7886 2500
Freddy Crossley, Emma Earl (Corporate Finance)
James Stearns (Corporate Broking)
Consilium Strategic Communications
Mary-Jane Elliott, Matthew Neal, Chris Gardner 0203 709 5700
About C4X Discovery
C4X Discovery (C4XD) aims to create the world's most productive Drug Discovery engine by using cutting-edge technologies and expertise to efficiently deliver best-in-class small-molecule medicines to clinical partners for the benefit of patients. The Company's business model focuses on replenishing big pharma discovery pipelines and driving returns through revenue generating pre-clinical licensing deals. In 2018, C4XD successfully out-licensed a pre-clinical programme in addictive disorders to Indivior in a deal worth up to $294m.
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to: www.c4xdiscovery.com
Notification and public disclosure of transactions by persons discharging managerial responsibilities and/or persons closely associated with them:
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Clive Dix | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Chief Executive Officer, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 1p ordinary shares
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 15 November 2019 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Craig Fox | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Chief Scientific Officer, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 1p ordinary shares
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 15 November 2019 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Natalie Walter | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Non-Executive Director, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 1p ordinary shares
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 15 November 2019 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name
| Harry Finch | ||||
2 | Reason for the notification | |||||
a) | Position/status
| Non-Executive Director, Director | ||||
b) | Initial notification/Amendment
| Initial Notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | C4X Discovery Holdings plc | ||||
b) | LEI | 213800UHNL82E323O870 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | 1p ordinary shares
ISIN GB00BQQ2RV18 | ||||
b) | Nature of the transaction
| Purchase of Ordinary Shares | ||||
c) | Price(s) and volume(s)
|
| ||||
d) | Aggregated information
|
| ||||
e) | Date of the transaction
| 15 November 2019 | ||||
f) | Place of the transaction
| London Stock Exchange - AIM | ||||
Name of authorised official of issuer responsible for making notification: Brad Hoy, Chief Financial Officer of the Company.
--ENDS-